Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsG v prasad

    G V Prasad

    Jump to

    • DRL may go for product filings in LatAM, APAC, North Africa

      The letter has resulted in a delay of some of important product launches this year and also necessitated a significant cost towards the remediation efforts, Prasad added.

    • Dr Reddy's to buy eight ANDAs in US for $350 mn

      The portfolio consists of products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business, the Hyderabad-based firm said.

    • Dr Reddy's to invest in startups

      "You cannot expect people to focus on increasing market share, growth, and driving the business while also disrupting the world. So for the disrupt part, we are re-architecting our organisation. This has to be outside the mainstream," DRL chief executive officer and co-chairman G V Prasad told global consultancy firm McKinsey in an interview.

    • Dr Reddy's gets USFDA nod to market Sernivo spray

      The company added the commercial launch of the product is planned for the coming quarter.

    • Microsoft interested in working with entrepreneurs: Nadella

      Addressing a gathering at T-Hub, a technological incubator promoted by the Telangana government, Nadella advised the start-up community to learn from the failures.

    • Dr Reddy's slips 4% even after it submits response to USFDA

      Last month, the country's second-largest drug maker had received a warning letter from the USFDA relating to two of its API manufacturing plants and a formulation plant in Andhra Pradesh and Telangana.

    • Dr Reddy's submits response to USFDA over warning letter

      In response to the letter, DRL CEO G V Prasad had said the company is in the process of shifting some of the products from these plants to other facilities and considering third party assessment for its plants.

    • DRL says taking corrective actions after FDA warning letter

      Dr Reddy's CEO G V Prasad said the company is in the process of shifting some of the products to other plants in the wake of warning letters. r

    • Dr Reddy's to launch Hepatitis C drug in India

      Dr Reddy's Laboratories today entered into an agreement with Hetero to distribute and market generic version of US-firm Gilead Sciences' Hepatitis C drug under the brand 'Resof' in India.

    • Business from Russia, US markets add to Dr Reddy's coffers

      G V Prasad, VC & CEO, Dr Reddy's Laboratories tells CNBC-TV18 that North America, Russia and the Pharmaceuticals Services and Active Ingredients (PSAI) segment led to the stupendous growth in the business.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347